Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

BACKGROUND: Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harbori...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Levacic, Danijela, Walbert, Tobias, Gan, Hui K, Vieito, Maria, Milhem, Mohammed M, Lipford, Kathryn, Forsyth, Sanjeev, Guichard, Sylvie M, Mikhailov, Yelena, Sedkov, Alexander, Brevard, Julie, Kelly, Patrick F, Mohamed, Hesham, Monga, Varun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825299/
https://www.ncbi.nlm.nih.gov/pubmed/35639513
http://dx.doi.org/10.1093/neuonc/noac139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825299/
https://www.ncbi.nlm.nih.gov/pubmed/35639513
http://dx.doi.org/10.1093/neuonc/noac139

Ejemplares similares